The MarketWatch News Department was not involved in the creation of this content. -- A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic ...

PSMA radioligand therapy is associated with significant reductions in PSA levels among select patients with metastatic prostate cancer, suggesting tumor responses. Prostate-specific membrane antigen ...

In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen deprivation therapy (ADT) and chemotherapy more than doubled biochemical ...

Concomitant G-CSF use in maintaining an efficacious dose and safe delivery of docetaxel in combination with darolutamide in patients with metastatic hormone sensitive prostate cancer (mHSPC): ARASENS, ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

The Prostate Cancer Foundation (PCF) today announced a $10 million unrestricted gift from an anonymous donor to launch a TACTICAL (Therapy ACceleration To Intercept CAncer Lethality) Award, which will ...

A renewed interest in radiopharmaceuticals has led to ground-breaking research and improved outcomes in patients with prostate cancer, according to experts. Radiopharmaceuticals have been used to ...

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...

SAN FRANCISCO -- Men with advanced prostate cancer and limited metastatic recurrence lived more than twice as long without disease progression when they received metastasis-directed radioactive ...

Reston, VA (October 13, 2025)--A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently and reliably assess prostate cancer progression or regression during ...

A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ...